These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25199921)

  • 1. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.
    Flory J; Haynes K; Leonard CE; Hennessy S
    Br J Clin Pharmacol; 2015 Feb; 79(2):330-6. PubMed ID: 25199921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
    Nies AT; Hofmann U; Resch C; Schaeffeler E; Rius M; Schwab M
    PLoS One; 2011; 6(7):e22163. PubMed ID: 21779389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
    Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
    Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics.
    Kim A; Chung I; Yoon SH; Yu KS; Lim KS; Cho JY; Lee H; Jang IJ; Chung JY
    Drug Metab Dispos; 2014 Jul; 42(7):1174-9. PubMed ID: 24764147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
    Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
    J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
    Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
    Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of organic cation transporters in drug-drug interaction.
    Koepsell H
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1619-33. PubMed ID: 26206523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.
    Cho SK; Kim CO; Park ES; Chung JY
    Br J Clin Pharmacol; 2014 Dec; 78(6):1426-32. PubMed ID: 25060604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes.
    Crouch MA; Mefford IN; Wade EU
    J Am Board Fam Med; 2012; 25(1):50-4. PubMed ID: 22218624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors.
    Tasnim J; Hashim NM; Han HC
    Cell Biochem Funct; 2024 Mar; 42(2):e3967. PubMed ID: 38480622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin.
    Li S; Xu B; Fan S; Kang B; Deng L; Chen D; Yang B; Tang F; He Z; Xue Y; Zhou JC
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1107-1117. PubMed ID: 36065506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.
    Christensen MM; Brasch-Andersen C; Green H; Nielsen F; Damkier P; Beck-Nielsen H; Brosen K
    Pharmacogenet Genomics; 2011 Dec; 21(12):837-50. PubMed ID: 21989078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches.
    Nguyen D; Miao X; Taskar K; Magee M; Gorycki P; Moore K; Tai G
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1238. PubMed ID: 38988092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
    Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
    Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
    Bhardwaj R; Morris B; Matschke K; Bertz R; Croop R; Liu J
    Clin Pharmacol Drug Dev; 2024 May; 13(5):465-473. PubMed ID: 38174905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1.
    Li L; Song F; Tu M; Wang K; Zhao L; Wu X; Zhou H; Xia Z; Jiang H
    Int J Pharm; 2014 Apr; 465(1-2):5-10. PubMed ID: 24530383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
    Luo L; Ramanathan R; Horlbogen L; Mathialagan S; Costales C; Vourvahis M; Holliman CL; Rodrigues AD
    Anal Chem; 2020 Jul; 92(14):9745-9754. PubMed ID: 32551505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.